Q4 2021 Xvivo Perfusion AB Earnings Call Transcript
Ladies and gentlemen, welcome to the XVIVO Group Report on Operations Q4 2021.
I will now hand over to Dag Andersson, CEO. Sir, please go ahead.
()-&
Thank you very much. So welcome to XVIVO Q4 call. And the presenters today, it's me Dag Andersson; and my CFO, Kristoffer Nordström. And I would like to start by summarizing some of the highlights. During the quarter, we had a very, let's say, interesting quarter, many things happened, positive things. We achieved, I must say, great organic growth in the quarter, 32%; and for the full year, 27%.
Earnings growth total amounted to 42% in the quarter, and adjusted EBITDA margin of 11%. The EBITDA number includes certain nonrecurring items amounting to approximately SEK 4 million, which Kristoffer will touch upon later. During fourth quarter and so -- and in connection with the acquisition of the U.S. company STAR Teams early November, we established a third business area, Services. So we now
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |